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Abstract
Objective—To examine the effect of travel distance and other sociodemographic factors on
access to a diagnosing provider for patients with melanoma.
Design—Analysis was performed of all incident cases of melanoma in 2000 from 42 North
Carolina counties.
Setting—Academic research.
Participants—Patients and providers from 42 North Carolina counties were geocoded to street
address.
Main Outcome Measures—Associations between Breslow thickness and clinical and
sociodemographic factors (age, sex, poverty rate, rurality, provider supply, and distance to
diagnosing provider) were examined.
Results—Of 643 eligible cases, 4.4% were excluded because of missing data. The median
Breslow thickness was 0.6 mm (range, 0.1–20.0 mm). The median distance to diagnosing provider
was 8 miles (range, 0–386 miles). For each 1-mile increase in distance, Breslow thickness
increased by 0.6% (P=.003). For each 1% increase in poverty rate, Breslow thickness increased by
1% (P=.04). Breslow thickness was 19% greater for patients aged 51 to 80 years than for those
aged 0 to 50 years (P=.02) and was 109% greater for patients older than 80 years than for those
aged 0 to 50 years (P<.001). Sex, rurality, and supply of dermatologists were not associated with
Breslow thickness.
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Conclusions—For patients with melanoma, distance to the diagnosing provider is a meaningful
measure of access that captures different information than community-level measures of rurality,
provider supply, and socioeconomic status. Future work should be targeted at identifying factors
that may affect distance to diagnosing provider and serve as barriers to melanoma care.
Survival for patients with melanoma is dependent on stage at diagnosis.1,2 As Breslow
thickness increases, overall survival decreases; 5-year overall survival is greater than 85%
for patients with Breslow thickness of less than 1.0 mm compared with less than 50% for
patients with Breslow thickness of greater than 4.0 mm.3 Consequently, early diagnosis may
substantially improve patient outcomes. Because melanoma can only be definitively
diagnosed based on biopsy findings, diagnosis requires detection of the suspicious lesion
and biopsy.4–7 Some primary care providers perform diagnostic biopsies, but many prefer to
refer patients to dermatologists or surgeons. As a result, early diagnosis often is dependent
on access to specialists who are comfortable diagnosing melanoma.
Access to health care is affected by sociodemographic factors such as income, education,
rurality, travel distance, and provider supply.8 By affecting access, these factors influence
patient care and outcomes. For cancer, sociodemographic factors have been associated with
incidence, stage at diagnosis, treatment, trial involvement, and prognosis.9–17 For melanoma
specifically, little is known about the relationships between sociodemographic factors and
patient outcomes. Findings from some studies1,18–22 suggest that education, socioeconomic
status, and physician supply may affect stage at diagnosis and survival, but the influence of
travel distance on access to care and outcomes for melanoma has not been considered, to our
knowledge. Our study seeks to fill this knowledge gap by exploring the effect of distance to
diagnosing provider on access to care for melanoma.
Although increased travel distance is generally viewed as a barrier to screening, early
diagnosis, and treatment, previous studies15,17,23–25 examining the role of travel distance for
patients with cancer have had mixed results. We hypothesize that for patients with
melanoma greater distance to a diagnosing provider is associated with increased Breslow
thickness or stage at diagnosis.
METHODS
Genes, Environment, and Melanoma is an international study that used a multisite
population-based ascertainment to examine causative factors associated with melanoma.26,27
The North Carolina (NC) ascertainment included all incident cases of invasive cutaneous
melanoma in 2000 from a 42-county area. Eligible cases were identified for the Genes,
Environment, and Melanoma study through collaboration with the NC Central Cancer
Registry. This registry collects data on all incident cases of invasive melanoma among NC
residents through mandatory reporting. State law allows use of deidentified data for
approved research. Hospitals are the primary sources of data, but these data are
supplemented with data from private physicians, pathology laboratories, and death
certificates. The registry obtains additional clinical information through direct review of
original medical records. For the Genes, Environment, and Melanoma study, all
dermatologists in the 42 counties were notified of the study, were encouraged to report cases
of melanoma to the registry, and were asked where their histopathology specimens were
processed. With separate institutional review board approval, the NC study population was
used for our study.
Diagnosis of melanoma often involves multiple providers; however, because definitive
diagnosis is made by histopathologic examination, the diagnosing provider was defined for
this study as the physician or physician extender who performed the initial biopsy, as
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identified from the pathology report. Patients and providers were geocoded to street address
using ArcView 9.0 and the StreetMap04 address locator (ESRI, Redlands, California).
Euclidian (straight line) distance was calculated between patient home and physician
office.28
Using a series of single-variable linear regressions of the natural log of Breslow thickness on
clinical and sociodemographic characteristics, bivariate associations were examined.
Because Breslow thickness was skewed, it was log transformed for analysis. Regression
coefficients for continuous measures are interpreted as the percentage change in tumor
thickness associated with a 1-U change in the measure. For characteristics captured as
dichotomous variables, the percentage change in tumor thickness compared with the referent
category is calculated by subtracting 1 from the exponent of the β coefficient (eβ−1).
The relationship between distance and the natural log of Breslow thickness was linear except
as distance reached extreme values. Consequently, distance was examined as a continuous
variable. A dummy variable created for the extreme values (99th percentile, >193 km [>120
miles]) was interacted on the continuous distance variable. Distance was also separately
examined as a dichotomous variable, using a conventional cut point (24 km [15 miles]).15
Census tract poverty rates represent the percentage of residents in the census tract living at
or below the 100% poverty line based on 2000 census information.29 Rurality was examined
using the Office of Management and Budget metropolitan classification system and the US
Department of Agriculture rural urban classification codes. Supply of dermatologists in a
county was examined 3 ways, namely, present or absent, absolute number, and density per
100 000 residents.
Two multiple log-linear regression models were investigated, one that included all
covariates and one that excluded characteristics that were statistically nonsignificant in the
bivariate analyses. The latter model was investigated because of the possibility that
statistically nonsignificant results were due to large SEs attributable to the somewhat large
number of variables relative to the number of observations. Statistical analyses were
performed using STATA 8 (StataCorp LP, College Station, Texas). All probability values
reflect the results of 2-sided tests and were considered statistically significant at P≤.05.
The same data set was used to identify factors that may affect distance to diagnosing
provider. Robust regression analysis was used to minimize error due to extreme values.
Additional factors examined included provider specialty and several measures of provider
supply. This information was obtained from the NC Health Professions Data System, which
tracks licensure data for all NC health care professionals.
RESULTS
There were 643 patients with at least 1 incident invasive cutaneous melanoma in the 42-
county NC ascertainment area in 2000. Twenty-eight cases (4.4%) were excluded because of
missing Breslow thickness or street address information; this included patients diagnosed as
having metastatic melanoma for whom no primary tumor was identified. Clinical and
sociodemographic characteristics of the remaining 615 patients are given in Table 1.
Two hundred seventy-seven distinct diagnosing providers were identified. Only 15 providers
diagnosed the melanomas in at least 1% (range, 0.2%–2.9%) of patients. All cases were
diagnosed by providers in NC. Ninety-nine percent of patients traveled less than 120 miles
to reach their diagnosing providers; the remaining 1% traveled between 233 and 386 miles.
Patients were mapped to street address, and distance to diagnosing provider was visually
examined (Figure 1). Although most patients who traveled long distances were from the
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same region, their melanomas were diagnosed by different providers at different institutions,
and no pattern could be identified. Within a given region, there was substantial variability in
distance, with some patients traveling short distances to reach their diagnosing providers and
other patients traveling much longer distances.
In the bivariate analysis, Breslow thickness was statistically significantly associated with
distance to diagnosing provider (Table 2). For distances not exceeding 120 miles, each 1-
mile increase in distance corresponded with a 0.6% increase in the mean Breslow thickness
(P=.003). In other words, each 10-mile increase in distance corresponded with a 6% increase
in Breslow thickness (Figure 2). After dichotomizing distance at 15 miles (75th percentile),
patients who traveled more than 15 miles had 20% thicker tumors on average than patients
who traveled 0 to 15 miles (P=.02).
Consistent with historical evidence,1,30–32 Breslow thickness was associated with age at
diagnosis (Table 2). The relationship between age at diagnosis and Breslow thickness was
nonlinear, so age was categorized as 0 to 50 years (245 cases), 51 to 80 years (329 cases), or
older than 80 years (41 cases). In the bivariate analysis, patients aged 51 to 80 years
averaged 19% thicker tumors than patients aged 0 to 50 years (P=.02), and patients older
than 80 years averaged 109% thicker tumors than patients aged 0 to 50 years (P<.001). Sex
and primary tumor site were unassociated with Breslow thickness (P>.05).
Poverty rate was statistically significantly associated with Breslow thickness in the bivariate
analysis; for every 1% increase in census tract poverty rate, Breslow thickness also
increased by 1% (P=.04). No association between Breslow thickness and rurality could be
identified using the Office of Management and Budget or US Department of Agriculture
classifications (P>.05). However, when patients were stratified as rural vs metropolitan, the
effect of distance to diagnosing provider on Breslow thickness seemed greater for cases
from rural areas compared with cases from metropolitan areas. Every 10-mile increase in
distance corresponded with a 10% increase in Breslow thickness (P=.06) for cases from
rural counties compared with a 5% increase in Breslow thickness (P=.03) for cases from
metropolitan counties.
The median Breslow thickness for cases diagnosed by dermatologists (0.5mm)was
statistically significantly less than the median Breslow thickness for cases diagnosed by
surgeons (1.04 mm) or by other providers (0.62 mm) (P<.001). When the supply of
dermatologists was examined using the density of dermatologists per 100 000 residents in
the county, there was no association between Breslow thickness and dermatologist supply
(P>.05). Similarly, there was no association between the dichotomous dermatologist present
or absent variable and Breslow thickness (P>.05). However, using the absolute number of
dermatologists, Breslow thickness decreased by 0.9% for every additional dermatologist in
the county (P=.004).
There was no statistically significant correlation between any of the sociodemographic
factors (distance, poverty, rurality, and dermatologist supply), so all were included in the
multivariate analysis. Because provider specialty cannot directly affect Breslow thickness,
provider specialty was not included in the multivariate model. After adjusting for other
factors, only age and distance to diagnosing provider were statistically significantly
associated with Breslow thickness (Table 2). Because estimates of some variables can be
unstable when the number of variables in the model is high relative to the number of
observations, the final model did not include gender, rurality, and primary tumor site.
Despite removal of these statistically nonsignificant variables, poverty rate and absolute
number of dermatologists were not statistically significantly associated with Breslow
thickness. Age remained statistically significantly associated with Breslow thickness in the
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multivariate analysis: patients aged 51 to 80 years had 16% thicker tumors than patients
aged 0 to 50 years (P=.04), and patients older than 80 years had 103% thicker tumors than
patients aged 0 to 50 years (P<.001). Similarly, distance to diagnosing provider was
statistically significant with each 10-mile increase in distance associated with a 6%increase
in Breslow thickness (P=.009). Even when the analysis was limited to tumors less than 2.0-
mm thick, Breslow thickness increased by 5% for every 10-mile increase in distance (P=.
002). Further exploration was performed to identify predictors of distance to diagnosing
provider. Age, sex, and primary tumor site were unassociated with distance to diagnosing
provider (P>.05) (Table 3). Although there was a statistically significant difference in
distance traveled according to the specialty of the provider, the difference was too small to
be clinically relevant: compared with patients whose melanomas were diagnosed by
dermatologists, patients whose melanomas were diagnosed by surgeons traveled on average
1.3 miles farther (P=.03). The difference in distance to diagnosing provider between patients
whose melanomas were diagnosed by dermatologists and those whose melanomas were
diagnosed by nonsurgeon and nondermatologist providers was not statistically significant.
The difference in distance to diagnosing provider based on poverty rate was also too small to
be clinically relevant: for every 1%increase in poverty rate, distance decreased by 0.1 miles
(P=.01).
Patients from rural counties traveled a modest 2.4 miles farther on average than patients
from metropolitan counties (P=.001). Using the US Department of Agriculture
classifications, distance to diagnosing provider was inversely related to the size of the town-
dwelling population of the county (Table 3). Compared with patients from metropolitan
areas, patients from rural areas were also older (mean age, 58.2 vs 53.7 years, P=.007) and
were more likely to live in poverty (12.3% vs 9.1%, P<.001). There were no statistically
significant differences in patient sex or provider specialty between cases from rural areas
and those from metropolitan areas.
Patients from counties with at least 1 dermatologist traveled on average 8.3 miles less than
patients from counties with no dermatologist (P<.001). This association was independent of
the specialty of the actual diagnosing physician. In other words, the presence of a
dermatologist resulted in a shorter mean distance, even for patients whose melanomas were
not actually diagnosed by a dermatologist, suggesting that the presence of a dermatologist
does not directly affect distance to diagnosing provider but rather is a marker of an increased
supply of local health care resources. To further explore this idea, the dermatologist variable
was replaced with other measures of physician supply (number of primary care physicians,
number of non–primary care physicians, and total number of physicians). Because they were
correlated, only 1 provider supply variable was included in the model at a time. The
relationships between each variable and distance to diagnosing provider were similar and
substantial, and the magnitudes of the effects of the other coefficients in the model were
stable regardless of which measure of provider supply was used.
COMMENT
Findings from previous studies1,18–22 suggest that education, socioeconomic status, and
physician supply may affect stage at diagnosis and prognosis for patients with melanoma.
MacKie and Hole18 examined the medical records of 3142 patients diagnosed as having
melanoma in Scotland between 1979 and 1993. They found that patients from the most
affluent areas were consistently more likely than those from the least affluent areas to be
diagnosed as having a melanoma less than 1.5 mm thick. In addition, patients from the most
affluent areas had better stage-adjusted 5-year disease-free survival than those from the least
affluent areas (81% vs 73%, P<.001). Similarly, examining the medical records of patients
with melanoma in Massachusetts from 1982 to 1987, Geller et al19 found that there was a
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higher mortality to incidence ratio for patients from lower socioeconomic status areas
compared with patients from more affluent areas (0.33 vs 0.27, P<.05), and patients from
lower socioeconomic status areas were more likely to have distant or regional metastases at
diagnosis (rate ratio, 1.64, 95% confidence interval, 1.20–2.25). Investigations of incident
melanoma cases in Florida in 1994 examined physician supply and rurality, as well as
socioeconomic status and education.20–22 Using area-based measures of each factor,
investigators found that advanced-stage disease, defined by distant or regional metastases,
was associated with education and physician supply but not with socioeconomic status or
rurality.
To our knowledge, this study is the first to examine distance to diagnosing provider and
area-based sociodemographic measures. Breslow thickness at diagnosis was directly related
to distance to diagnosing provider, but there were no statistically significant associations
between poverty rate, rurality, or provider supply and Breslow thickness. It is possible that
associations existed but were too small to detect in a study of this size. However, the
differences between our findings and those of previous investigators18,19 might also be
attributed to the inclusion of potential confounders such as patient age and travel distance.
Because provider specialty cannot directly affect Breslow thickness, provider specialty was
not included in our multivariate analysis of factors affecting Breslow thickness. Still, the
differences in Breslow thickness among different types of providers are interesting. In
general, dermatologists may perform a larger volume of routine screening skin examinations
than other providers. Consequently, the smaller Breslow thickness for cases diagnosed by
dermatologists compared with those diagnosed by surgeons and other providers may reflect
the effect of screening on early detection of melanoma.
DISTANCE TO DIAGNOSING PROVIDER
Little is known about the relationship between distance to diagnosing provider and stage at
diagnosis for patients with cancer. Rushton et al33 examined distance to diagnosing provider
for patients with colon cancer and found that patients who traveled longer distances were
more likely to be diagnosed as having late-stage disease. In our study, Breslow thickness
increased 0.6% for every 1-mile increase in distance to diagnosing provider. Consequently, a
10- to 15-mile increase in distance could explain a clinically relevant difference in Breslow
thickness. The relationship between distance to diagnosing provider and Breslow thickness
was linear for all travel distances except the most extreme: Breslow thickness began to
decline for the 1% of patients who traveled more than 120 miles. These cases may represent
statistical outliers, or they may be systematically different from the remainder of the
population. Studies15,24 have shown a protective benefit for patients who travel long
distances; it is theorized that these cases represent the most empowered patients, who are not
hindered by barriers such as travel distance.
Investigations addressing travel distance often examine distance to the nearest provider,
which is by definition a proxy for geographic isolation.17 We found that many patients
bypassed local providers on their way to the actual diagnosing provider (Figure 1).
Consequently, we know that distance to diagnosing provider captures more than just
distance to the nearest provider. Of the factors examined, the greatest predictor of distance
to diagnosing provider was the supply of providers in the county. Still, only a few clinical
and sociodemographic factors could be explored using our data set. It is likely that many
other factors influence distance to diagnosing provider. Most important, the role of the
referring provider and the effect of health insurance could not be explored. The conceptual
model shown in Figure 3 includes some of the factors that may ultimately affect the
“choice” of diagnosing provider. Further work is needed to delineate which factors most
directly affect distance, and consequently access, to the diagnosing physician.
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Euclidian distance was used for this study. Although not as precise as road distance,
Euclidian distance has been shown to be a meaningful measure of travel distance for
geographic areas without major topographical barriers.28 Our study was limited by the
chosen ascertainment area of the Genes, Environment, and Melanoma study. Although many
rural counties were included, some mountain and coastal areas of the state were not
included. These excluded areas contain substantial topographical barriers, including
mountains and waterways. While this limits generalizability of our results, it is reasonable to
infer that any disparity identified based on rurality or distance to diagnosing provider would
only be magnified if more geographically isolated areas were included.
Referral bias can confound attempts to examine the effect of distance to diagnosing
provider. For tumors in which the size is apparent before a diagnosis is confirmed, large
tumors may be preferentially referred to high-volume centers. Because Breslow thickness
cannot be accurately determined without a biopsy specimen,34 this should not have been an
issue in our study. Still, there is some evidence to suggest that careful clinical examination
combined with dermatoscopic examination can differentiate thin melanomas from
intermediate or thick lesions.35 As a result, it is possible that some patients were referred to
surgeons before a biopsy was performed based solely on worrisome clinical examination.
Such referral bias could contribute to the differences in the mean thickness between
melanomas diagnosed by dermatologists and those diagnosed by surgeons. However,
patients whose melanomas were diagnosed by surgeons traveled on average only 1.3 miles
farther than patients whose melanomas were diagnosed by dermatologists. Consequently,
preferential referral of worrisome lesions to surgeons alone cannot explain the relationship
between Breslow thickness and travel distance. Further support for the limited role of
referral bias is provided by the fact that fewer than 5% of patients had tumors greater than
4.0mmthick, and the relationship between distance and Breslow thickness was constant even
when cases with tumors greater than 2.0 mm thick were excluded from analysis.
Information on the interval between initial patient encounter and diagnostic biopsy was
unavailable for this study. The relationship between distance traveled and delay in diagnosis
should be addressed in future studies. It is likely that time to diagnosis and travel distance
are intermediate outcome measures that capture similar information about access to care.
CONCLUSIONS
For this population, distance to diagnosing provider seems to be a more complete measure of
access to a melanoma diagnosis than proxy measures of rurality, socioeconomic status, and
provider supply. Distance to diagnosing provider is not simply a measure of geographic
isolation, as many patients bypass closer providers on their way to the diagnosing provider.
The farther that patients travel to reach their diagnosing providers, the more advanced their
stage at diagnosis is likely to be. Although we do not yet have survival data, it is reasonable
to surmise that differences in Breslow thickness at diagnosis could translate into differences
in overall survival.1,3 However, on a population-level these differences will likely be too
small to be meaningful or to even detect because most patients are diagnosed as having thin
melanoma and already have greater than 90% survival.
Further work is needed to characterize the determinants of distance to diagnosing provider,
as well as the pathways and barriers to melanoma care. Once potential barriers are
identified, interventions can be developed to minimize the effect of travel distance and other
sociodemographic factors on access to melanoma care. Such interventions could potentially
translate to other settings in which access to specialists is critical to patient outcomes.
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Distance traveled to diagnosing provider. Each data point represents the location of an
incident case of melanoma. Points are color coded according to distance traveled to
diagnosing provider.
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Bivariate relationship between Breslow thickness and distance traveled to diagnosing
provider. The natural log of Breslow thickness is plotted against the distance traveled for a
given case. The line represents the lowess, a locally weighted regression of the natural log of
Breslow thickness on distance traveled. The bandwidth for the regression is 0.8. The 1% of
outlier patients who traveled more than 120 miles were excluded.
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Conceptual model of factors that may affect distance to diagnosing provider.
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Table 1
Clinical and Sociodemographic Characteristics of the Study Populationa
Characteristic No.b Median (Range)
Breslow thickness, mm 615 0.6 (0.1–20.0)
Distance to diagnosing provider, miles 615 8 (0–386)
Age, y 614 55 (10–97)
Census tract poverty rate 615 8.1 (0.7–43.9)
Dermatologists in county, No. 615 6 (0–30)
Density of dermatologists in county, No. per 100 000 population 615 4.3 (0–19.5)
T classification
 1 426 69.3
 2 116 18.9
 3 45 7.3
 4 28 4.5
Sex
 Male 333 54.1
 Female 282 45.9
Rurality
 Metropolitan 478 77.7
 Rural 137 22.3
Dermatologists in county
 Present 530 86.2
 Absent 85 13.8
Primary tumor site
 Head or neck 121 20.3
 Trunk 263 44.0
 Upper extremity 116 19.4
 Lower extremity 97 16.3
Specialty of diagnosing provider
 Dermatologist 373 63.2
 Surgeon 171 29.0
 Other 46 7.8
a
Data are given as percentages unless otherwise indicated.
b
The total number of participants varies because of missing data.
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Table 2
Predictors of Breslow Thickness at Diagnosis
Predictor
% Change (95% Confidence Interval)a
Bivariate
R2 = 0.07
Multivariate, All Variables (n = 596)
Multivariate, Final Model (n =
614)
Distance traveled, 0–12 miles,
continuous
0.6 (0.2 to 1.1)b 0.5 (0.1 to 1.0)c 0.6 (0.1 to 1.0)b
Distance traveled, 120–386 miles,
continuous
−1.20 (−2.20 to −0.04)c −1.10 (−2.10 to −0.03)c −1.10 (−2.10 to −0.06)c
Age, y
 0–50 1 [Reference] 1 [Reference] 1 [Reference]
 51–80 19.2 (3.4 to 37.3)c 14.0 (−1.9 to 32.4) 16.3 (0.9 to 34.1)c
 > 80 108.9 (57.4 to 177.2)d 101.7 (49.9 to 171.3)d 102.7 (53.0 to 168.5)d
Census tract poverty rate, continuous 1.00 (0.06 to 2.00)c 0.3 (−0.7 to 1.3) 0.6 (−0.4 to 1.6)
Dermatologists in county,
continuous
−0.9 (−1.5 to −0.3)b −0.70 (−1.40 to 0.02) −0.5 (−1.1 to 0.1)
Primary tumor site …
 Head or neck 17.7 (−2.4 to 42.0) 4.8 (−13.5 to 27.0)
 Trunk 1 [Reference] 1 [Reference]
 Upper extremity 6.1 (−12.3 to 28.3) 3.1 (−14.9 to 24.9)
 Lower extremity 10.8 (−9.5 to 35.7) 10.1 (−10.5 to 35.3)
Sex …
 Female 1 [Reference] 1 [Reference]
 Male 6.5 (−7.3 to 22.3) 7.6 (−7.0 to 24.4)
Rurality …
 Metropolitan 1 [Reference] 1 [Reference]
 Rural 5.1 (−11.0 to 24.1) −8.7 (−24.3 to 10.2)
Abbreviation: Ellipses, not applicable.
a
Results are given as the percentage change in Breslow thickness associated with a 1-U change in the independent variable. For patient
characteristics that are captured as dichotomous variables (categorical variables), the percentage change in tumor thickness compared with the
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Table 3
Predictors of Distance to Diagnosing Provider
Predictor
Change (95% Confidence Interval)a
Bivariate Multivariate, All Variables (n = 595)
Age, continuous −0.007 (−0.040 to 0.030) −0.020 (−0.050 to 0.008)
Census tract poverty rate, continuous −0.005 (−0.090 to 0.080) −0.10 (−0.18 to −0.02)b
Dermatologists in county, present or absent −10.44 (−11.92 to −8.96)c −8.27 (−9.95 to −6.59)c
Primary tumor site
 Head or neck 0.10 (−1.56 to 1.76) 0.64 (−0.83 to 2.11)
 Trunk 1 [Reference] 1 [Reference]
 Upper extremity −0.28 (−1.97 to 1.40) −0.37 (−1.84 to 1.11)
 Lower extremity −0.07 (−1.87 to 1.73) −0.16 (−1.74 to 1.42)
Sex
 Female 1 [Reference] 1 [Reference]
 Male 0.48 (−0.73 to 1.69) −0.13 (−1.26 to 0.99)
Ruralityd
 <2500 Nonmetropolitan 15.87 (10.05 to 21.69)c 8.94 (3.28 to 14.61)e
 2500–20 000 Nonmetropolitan 18.64 (14.43 to 22.84)c 14.38 (10.39 to 18.36)c
 >20 000 Nonmetropolitan 5.68 (2.23 to 9.13)c 3.25 (−0.01 to 6.52)
 <250 000 Metropolitan 2.07 (−1.68 to 5.83) 1.87 (−1.67 to 5.42)
 250 000–1 000 000 Metropolitan 3.16 (−0.08 to 6.40) 2.49 (−0.52 to 5.51)
 >1 000 000 Metropolitan 1 [Reference] 1 [Reference]
Specialty of diagnosing provider
 Dermatologist 1 [Reference] 1 [Reference]
 Surgeon 1.45 (0.14 to 2.77)b 1.29 (0.11 to 2.47)b
 Other −2.88 (−13.24 to 7.49) −2.43 (−11.46 to 6.60)
a
Results are given as the absolute change in distance in miles associated with a 1-U change in the independent variable. For dichotomous variables,
this is the absolute change in distance in miles compared with the reference category. The specialty of the diagnosing provider was unavailable for






Rurality based on US Department of Agriculture Rural Urban Classification Codes. Numbers represent the size of the town-dwelling population
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